Previously, small cell lung cancer (SCLC) treatment has been confined to chemotherapy, so additional treatment options is a priority in combating SCLC. Nowadays, immunotherapeutic agents have been approved for various cancer types, including NSCLC. To assess whether immunotherapy is suitable for SCLC, researchers conducted a phase I/II CheckMate 032 study comprised of two cohorts of patients. The two cohorts recruited recurrent SCLC patients to assess the efficacy of combination of nivolumab and ipilimumab treatments. The pooled results in the first cohort showed that the objective response rate (ORR) was 22% and 11% in the combination group and the ipilimumab monotherapy group, respectively. In the second cohort, the 3-month progression free survival (PFS) rate was 30% and 18% in the combination group and the ipilimumab monotherapy, respectively. These findings suggest that treatment with nivolumab + ipilimumab may demonstrate durable response in recurrent SCLC patients.
2. ASCO 2017: